AgingResearch.News
AAIC 2025 Abstract

Bumetanide in Patients with Alzheimer's Disease (BumxAD): A Phase IIa Clinical Trial

By Mina Kmiecik, Minhtrang Chu, Annie Zhou, Show 10 more authorsKyan Younes
Interventions
Paper

Abstract

Background: Bumetanide is a potent diuretic administered orally and is FDA approved for the treatment of edema and hypertension.

The paper

Mina Kmiecik, Minhtrang Chu, Annie Zhou, Show 10 more authorsKyan Younes

Stanford University

AAIC 2025 Abstract, 25 Dec 2025, CC BY

Presented at AAIC 2025

doi.org/10.1002/alz70859_106859

Related